1. Clinical & Scientific Overview
Bleomycin Sulfate (TIP-MED-000559, Reference Code [ONC-10]) is classified under
Oncology & Antineoplastic Medicines as a Antitumour Antibiotic (G2/M Phase Specific) • Glycopeptide Radiomimetic Antitumour Antibiotic.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Bleocel (Celon Laboratories), Bleocin (Nippon Kayaku / Fresenius Kabi), Bleo-N (Neon Laboratories)
Lyophilised Powder for Injection: 15 IU (15 Units) vial
Oncology Specialisation & Cytotoxic Safety Protocol
Antitumour Antibiotic (G2/M Phase Specific)
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: ABVD: 10 IU/m2 IV on Days 1 and 15 of a 28-day cycle; maximum lifetime cumulative dose: 400 IU (units).
Signature Dose-Limiting Toxicities & Organ Monitoring: DOSE-LIMITING PULMONARY FIBROSIS / PNEUMONITIS (10% incidence, 1–2% fatal): Risk rises sharply above 400 IU cumulative dose, age >70, renal impairment (renally excreted), and exposure to high FiO2 supplemental oxygen during anaesthesia; cutaneous flagellate hyperpigmentation (whip-like linear streaks triggered by scratching) and acute idiosyncratic hyperpyrexia.
Extravasation, Premedication & Safe Cytotoxic Handling: Monitor pulmonary function (DLCO — discontinue if DLCO drops >15–20%); alert anaesthetists on patient medical bracelet to maintain minimum FiO2 (<25–30%) needed to keep SpO2 89–92% during any future surgery!
3. Mechanism of Action & Pharmacodynamics
Chelates ferrous iron (Fe2+) and reacts with molecular oxygen to generate superoxide and hydroxyl radicals that abstract hydrogen atoms from deoxyribose, causing single- and double-stranded DNA scission; inactivated in most tissues by Bleomycin Hydrolase, which is deficient in lungs and skin.
4. Therapeutic Indications & Evidence-Supported Uses
- Hodgkin Lymphoma (ABVD regimen)
- Testicular Germ Cell Tumours (BEP regimen)
- Malignant pleural effusion pleurodesis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): ABVD: 10 IU/m2 IV on Days 1 and 15 of a 28-day cycle; maximum lifetime cumulative dose: 400 IU (units).
Administration & Meal Timing: ABVD: 10 IU/m2 IV on Days 1 and 15 of a 28-day cycle; maximum lifetime cumulative dose: 400 IU (units).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Bleomycin or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: DOSE-LIMITING PULMONARY FIBROSIS / PNEUMONITIS (10% incidence, 1–2% fatal): Risk rises sharply above 400 IU cumulative dose, age >70, renal impairment (renally excreted), and exposure to high FiO2 supplemental oxygen during anaesthesia; cutaneous flagellate hyperpigmentation (whip-like linear streaks triggered by scratching) and acute idiosyncratic hyperpyrexia.
8. Adverse Effects Profile
- DOSE-LIMITING PULMONARY FIBROSIS / PNEUMONITIS (10% incidence, 1–2% fatal): Risk rises sharply above 400 IU cumulative dose, age >70, renal impairment (renally excreted), and exposure to high FiO2 supplemental oxygen during anaesthesia; cutaneous flagellate hyperpigmentation (whip-like linear streaks triggered by scratching) and acute idiosyncratic hyperpyrexia.
- DOSE-LIMITING PULMONARY FIBROSIS / PNEUMONITIS (10% incidence, 1–2% fatal): Risk rises sharply above 400 IU cumulative dose, age >70, renal impairment (renally excreted), and exposure to high FiO2 supplemental oxygen during anaesthesia; cutaneous flagellate hyperpigmentation (whip-like linear streaks triggered by scratching) and acute idiosyncratic hyperpyrexia.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- DOSE-LIMITING PULMONARY FIBROSIS / PNEUMONITIS (10% incidence, 1–2% fatal): Risk rises sharply above 400 IU cumulative dose, age >70, renal impairment (renally excreted), and exposure to high FiO2 supplemental oxygen during anaesthesia; cutaneous flagellate hyperpigmentation (whip-like linear streaks triggered by scratching) and acute idiosyncratic hyperpyrexia.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor pulmonary function (DLCO — discontinue if DLCO drops >15–20%); alert anaesthetists on patient medical bracelet to maintain minimum FiO2 (<25–30%) needed to keep SpO2 89–92% during any future surgery!
Pharmacist Patient Counselling Points:
- Monitor pulmonary function (DLCO — discontinue if DLCO drops >15–20%); alert anaesthetists on patient medical bracelet to maintain minimum FiO2 (<25–30%) needed to keep SpO2 89–92% during any future surgery!
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Monitor pulmonary function (DLCO — discontinue if DLCO drops >15–20%); alert anaesthetists on patient medical bracelet to maintain minimum FiO2 (<25–30%) needed to keep SpO2 89–92% during any future surgery!
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-09] Daunorubicin Hydrochloride — Anthracycline Cytotoxic Antibiotic • Anthracycline Antileukaemic
- [ONC-11] Carboplatin — Platinum Alkylating-Like Agent • Second-Generation Platinum Coord
- [ONC-12] Oxaliplatin — Platinum Alkylating-Like Agent • Third-Generation Diaminocyclohex
- [ONC-13] Docetaxel — Antimitotic Taxane (M-Phase Specific) • Semisynthetic Taxane Micr
